Nephrology Drugs Market Expected To Reach $24.31 Billion By 2030 As Growth Accelerates At 6.7% CAGR
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Nephrology Drugs Market Size, Value And Growth Trends Through 2030
The nephrology drugs market has experienced notable expansion over recent years, with projections indicating growth from $17.69 billion in 2025 to $18.74 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.9%. This upward trajectory in the historic period has been driven by factors such as the early uptake of antihypertensive medications, a rising prevalence of chronic kidney disease, enhanced hospital infrastructure dedicated to renal care, progress in dialysis and parenteral therapies, and increased public awareness about kidney-related conditions.
The nephrology drugs market is projected to experience robust expansion in the coming years, reaching a valuation of $24.32 billion by 2030 with a compound annual growth rate (CAGR) of 6.7%. This anticipated growth during the forecast period is driven by several factors, including the advancement of precision medicine tailored for nephrology, the incorporation of artificial intelligence into renal drug development, the expansion of homecare treatment options, increased investment in biotechnology targeting kidney therapies, and the widespread use of digital health monitoring systems for kidney patients. Key trends shaping the forecast period encompass personalized kidney care strategies, a growing incidence of hypertension-related kidney disorders, innovations in renal drug formulations, enhanced awareness surrounding chronic kidney disease management, and a rising preference for home-based renal treatments.
Download A Free Sample Report For Comprehensive Market Insights:
Nephrology Drugs Market Growth Drivers And Industry Catalysts
The increasing occurrence of chronic kidney disease is anticipated to drive forward the expansion of the nephrology drugs market. Chronic kidney disease (CKD) is characterized by impaired kidneys that cannot filter blood as efficiently as required, with damage developing slowly over an extended period, leading to potential waste buildup in the body. Medications for nephrology are mainly used to manage CKD by improving renal function and decelerating the disease’s progression, thereby preventing further harm to the body—this in turn fuels the market for nephrology drugs. As an example, in June 2023, according to the Oxford Academic, a research platform from the UK-based Oxford University Press, the prevalence of CKD in the UK is expected to increase by 4% from 8.27 million to 8.61 million individuals between 2022 and 2032, with stage distribution in 2032 projected at 30.36% for stage 1, 21.07% for stage 2, 29.78% for stage 3a, 11.86% for stage 3b, 4.15% for stage 4, and 2.78% for stage 5. Consequently, the growing prevalence of chronic kidney disease is propelling the growth of the nephrology drug market.
Nephrology Drugs Market Segment Performance And Strategic Opportunities
The nephrology drugs market covered in this report is segmented –
1) By Drugs: Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Other Drugs
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Antihypertensive Agents: Calcium Channel Blockers, Beta-Blockers, Angiotensin II Receptor Blockers (ARBs)
2) By Erythropoiesis-Stimulating Agents: Epoetin Alfa, Darbepoetin Alfa
3) By Diuretics: Loop Diuretics, Thiazide Diuretics, Potassium-Sparing Diuretics
4) By ACE Inhibitors: Lisinopril, Enalapril
5) By Antidiabetic Agents: Metformin, Insulin
6) By Other Drugs: Phosphate Binders, Vitamin D Analogues, Renin Inhibitors
Nephrology Drugs Market Trends Influencing Long-Term Demand
Leading players in the nephrology drugs market are prioritizing approvals for innovative therapies, such as the U.S. Food and Drug Administration’s endorsement of Jardiance (empagliflozin), in order to address the demands of their current customer base more effectively. Empagliflozin functions as a diabetes medication, specifically designed to manage and treat type 2 diabetes mellitus. This drug falls under the sodium-glucose co-transporter (SGLT-2) classification of diabetic treatments. By prompting the kidneys to eliminate a larger amount of glucose through urine, empagliflozin effectively lowers blood sugar levels. A notable example occurred in January 2023, when Eli Lilly and Company, a pharmaceutical firm based in the United States, together with Boehringer Ingelheim, a German pharmaceutical company, revealed that the FDA had granted approval for a supplemental New Drug Application (sNDA) concerning Jardiance (empagliflozin) tablets. These tablets are being assessed as a possible treatment to reduce the likelihood of kidney disease progression and cardiovascular death among adults suffering from chronic kidney disease (CKD).
Nephrology Drugs Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the nephrology drugs market are AstraZeneca plc, AbbVie Inc., Akebia Therapeutics Inc., Amgen Inc., FibroGen Inc., Johnson And Johnson, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Reata Pharmaceuticals Inc., Ardelyx Inc., Novo Nordisk A/S, Novartis AG, Baxter International Inc., Bristol Myers Squibb Company, Kissei Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals, OPKO Health Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Vifor Pharma Group, Bayer AG, Otsuka Pharmaceutical Co. Ltd., Mylan N.V.
Access The Complete Nephrology Drugs Market Report:
Nephrology Drugs Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the nephrology drug market in 2025. Europe will be the second-largest growing region in the nephrology drug market in 2025. The regions covered in the nephrology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
